Business
Resverlogix Launches Phase IIb ASSURE Trial for RVX-208 Cholesterol Transport Drug, Safety Data Completed and Filed
Jun. 13, 2011 (Canada NewsWire Group) -- TSX Exchange Symbol: RVX CALGARY, June 13, 201...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n Jun. 13, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, June 13, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the\n "Company") (TSX:RVX) announced today that the Company has completed its\n chronic repeated-dose toxicology studies on its lead compound, RVX-208,\n indicated for the reduction and prevention of atherosclerosis.  These\n chronic toxicology studies support the initiation of its longer\n duration, Phase IIb, clinical trial ASSURE. As a first-in-class\n compound, RVX-208 underwent six and twelve month testing in rodents and\n non-rodents, respectively, and the analysis, results and reporting of\n these studies to the appropriate regulatory authorities, have been\n completed.\n\n\nWith the safety studies complete, RVX-208 can now advance into trials of\n more than three months duration. The Phase IIb ASSURE trial, in which\n Intra Vascular Ultra Sound (IVUS) technology will be used to determine\n coronary arterial plaque regression, will have a treatment duration of\n six months.  The IVUS measurement will be used as the trial's primary\n endpoint.\n\n\nResults from the recently completed ASSERT trial strongly demonstrate\n that RVX-208 is efficacious in elevating new production of ApoA-1, the\n key protein in 'good cholesterol', HDL cholesterol and HDL Alpha1 sub\n particles. None of these reverse cholesterol transport biomarkers\n appear to have reached their plateaus at the completion o...